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Abstract
Background: Oral squamous cell carcinoma (OSCC) accounts over 90% of malignant neoplasms of the oral cavity.
This pathological entity is associated to a high mortality rate that has remained unchanged over the past decades.
Tumour-associated macrophages (TAMs) are believed to have potential involvement in OSCC progression. However,
the molecular networks involved in communication between stroma and cancer cells have not yet been fully
elucidated.
Main body: The role of M2 polarized cells in oral carcinogenesis is supported by a correlation between TAMs
accumulation into OSCC stroma and poor clinical outcome. Signalling pathways such as the NF-κB and cytokines
released in the tumour microenvironment promote a bidirectional cross-talk between M2 and OSCC cells. These
interactions consequently result in an increased proliferation of malignant cells and enhances aggressiveness, thus
reducing patients’ survival time.
Conclusions: Here, we present a comprehensive review of the role of interleukin (IL)-1, IL-4, IL-6, IL-8, IL-10 and the
receptor tyrosine kinase Axl in macrophage polarization to an M2 phenotype and OSCC progression. Understanding
the molecular basis of oral carcinogenesis and metastatic spread of OSCC would promote the development of
targeted treatment contributing to a more favourable prognosis.
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Background
Cancer pathogenesis events take place in imbalanced mi-
croenvironments, where pathological states do not affect
only neoplastic cells [1–3]. Instead, cancerous cells dis-
rupt tissue homeostasis, disturbing different cell types
and contributing to disease progression, through interac-
tions with mediators of the immune system [4–6]. Oral
squamous cell carcinoma (OSCC) is a solid tumour of
epithelial origin that affects more than 400,000 individ-
uals annually worldwide [7]. The mortality rate of this
disease has remained largely unchanged for the last
decades, with a 5-year survival under 50% [8]. There is
compelling evidence that tumour-associated macrophages
(TAMs) have potential involvement in the progression
and metastatic spread of OSCC. The most important
features associated with their presence in the lesion
stroma include facilitation of angiogenesis, tumour cell
invasion, augmentation of cell motility, persistent
growth, and suppression of anti-tumour responses [9–
13]. The signals involved in communication between
tumour cells and macrophages have not yet been com-
pletely elucidated. However, the interaction among
tumour and inflammatory cells seems to be bidirec-
tional [14]. Here, we present the strategies by which
tumour cells influence macrophage physiology to dis-
play a pro-tumour phenotype, and the contribution of
TAMs to OSCC progression. Is given an overview of
potential markers that could provide support for diag-
nostic, evaluation of clinical outcome, and be used as
valuable antineoplastic targets.
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Macrophage differentiation
In adults, inflammatory monocytes (CD64+/CD16- CCR2+
Ly6C+) constitutively originate tissue-resident macrophage
populations [15, 16]. The exposure of these cells to micro-
environmental stimuli results in complex phenotypic
modifications in a time- and location-dependent manner
[17–19]. The activation of different regulatory mecha-
nisms and transcription pathways result in a vast
spectrum of macrophage subtypes, of which M1 and M2
represent the extreme polarization phenotypes [18, 19].
The M1 polarization state depends on microbial stimulus
and a T helper type 1 (TH1) cytokine profile (classical acti-
vation pathway). Whereas M2 polarization depends on a
T helper type 2 (TH2) cytokine profile (alternative activa-
tion pathway) [20]. Interferon-gamma (INF-γ ) and inter-
leukin (IL)-4 secretion sustain an M1 and an M2
phenotype commitment, respectively [21]. M1 are innate
immune effector cells that fight intracellular microbial
challenges by means of reactive oxygen species and nitro-
gen intermediates. Activation of signal transducer and ac-
tivator of transcription (STAT)-1 in M1 macrophages is
important for optimal TH1 responses [22], such as direct
tumour cell death [23, 24]. M2 macrophages block TH1
and differentiate in the tumour stroma from blood mono-
cytes, or resident macrophages in resting state, after mak-
ing contact with neoplastic cells presenting aberrant
production of certain cytokines [18]. Additionally, they
promote cancer progression by STAT-3 activation, indu-
cing and maintaining a pro-carcinogenic inflammatory
microenvironment [25].
OSCC cells and TAM interactions
Histopathologically, OSCC presents as fibrous connect-
ive tissue with unusual amounts of extracellular matrix
rich in fibroblasts, vascular vessels, and inflammatory
cells [26]. Among the local milieu of OSCC stromal
spaces, rich in perlecans and inflammatory cells, mono-
cytes or resting macrophages are differentiated into
LyC16high, CD163+, CD204+, and CD68+ expressing
TAMs. These cells are considered of utmost biological
importance for disease progression and correlate with
increased dedifferentiation in primary tumour sites [27–
29]. Moreover, TAMs elicit tumour relapse and/or post-
operative cervical lymph node metastasis via angiogen-
esis and suppression of anti-tumour immunity [9]. An
increase in the number of CD163+ macrophages occurs
in oral leukoplakia. However, they co-express phosphor-
ylated STAT-1, suggesting that in premalignant lesions
TAMs possess an M1 phenotype in a dominant TH1
microenvironment [30]. Polarization to an M2 TAM
phenotype probably occurs gradually and early during
the onset of cancer. It is suggested that several interleu-
kins (IL-1, IL-4, IL-6, IL-8, and IL-10), and other factors,
such as the receptor tyrosine kinase Axl, participate in
promoting this phenomenon. In the next sections we
propose a topic structured discussion of relevant find-
ings that corroborate this theoretical assumption. Fig-
ure 1 briefly reviews the effect of interleukins on TAMs
present in OSCC stroma.
IL-1
Tumour released IL-1 cross-talks to TAMs and induces
M2 polarization to an immunosuppressive phenotype
via IL-1 receptor (IL-1R) and myeloid differentiation pri-
mary response gene 88 (MyD88), which requires I-
kappaB kinase beta (IKKβ)-mediated nuclear factor
kappa B (NF-κB) [31, 32]. Interleukin-1 beta (IL-1β) is a
critical mediator of chronic inflammation and is impli-
cated in OSCC during early and late stages of carcino-
genesis. Pro-IL-1β is upregulated in tobacco and betel
quid related oral cancer, and is secreted in an
inflammasome-dependent manner [33], although it is
absent in homeostatic conditions. In the presence of IL-
1β TAMs suffer an upregulation of C-X-C motif chemo-
kine receptors (CXCR), especially CXCR4, induced by
the activation of extracellular signal regulated MAP kin-
ase (ERK). Macrophages then become attracted by
CXCR4 ligands, like stromal cell derived factor-1 alpha
(SDF-1α) [34]. SDF-1α is highly inducible in hypoxic
and proangiogenic niches, where it reinforces the auto-
crine/paracrine loop that contributes to an M2 pheno-
type [35]. Nevertheless, OSCC cells and TAMs together
through IL-1β/IL-1R and CXCR4/ SDF-1α and via acti-
vation of the ERK signalling pathway produce tumour
cell migration and invasion by inducing expression of
matrix metalloproteinase (MMP) enzymes MMP-9 and
MMP-13 [36]. These important angiogenic modulating
enzymes promote the acquisition of vasculature for oxy-
genation, nutrition, and waste disposal, which are of fun-
damental importance for tumour growth [2]. Contrarily,
the blockade of CXCR4 by the antagonist 1,1′-[1,4-phe-
nylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetrade-
cane octahydrochloride (AMD3100) inhibited SDF-1
mediated lymph node metastasis [37]. Furthermore, a
rich IL-1β microenvironment promotes CXCL1 pro-
duction, and through CXCR2 this induces tyrosine
phosphorylation of the endothelial growth factor recep-
tor (EGFR) [33]. As a result, EGFR activates pathways
leading to cell growth, DNA synthesis, and the expres-
sion of oncogenes like fos and jun [38]. IL-1α is found
in tumour cell membranes and in intracellular loca-
tions, and is produced in larger amounts than IL-1β in
highly metastatic tumours. Despite the lack of evidence
that demonstrates its direct participation in OSCC
progression through macrophage activation, IL-1α in-
teracts with fibroblasts in the stroma. Therefore, IL-
1α acts promoting cell proliferation and upregulating
the secretion of IL-8, CXCL-1, and chemokine C-C
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motif ligand (CCL)-7 [39]. Coincidently, these cyto-
kines are also commonly produced by TAMs, rising the
hypothesis of a plausible interaction between OSCC and
M2 cells by means of IL-1α.
IL-4
IL-4 is an anti-inflammatory and immunomodulatory
cytokine that has been identified as a relevant factor for
the activation of TAMs, as well as IL-1. Furthermore, an
increased expression of IL-4 receptor alpha (IL-4Rα)
correlates with increased OSCC recurrence [40]. Regard-
ing this tumour entity, the interaction between malig-
nant cells and TAMs occurs through the plasminogen
activator urokinase (uPA) and its specific receptor uPAR,
mainly through the activation of ERK1/2 and increase in
the production of IL-4. In OSCC cells this receptor
modifies several transduction pathways, affecting neo-
plastic cell behaviours and acts as a promoter of survival,
proliferation, and metastasis [41–43]. The high levels of
IL-4 produced modifies the tumour microenvironment
and facilitates an increase in arginase-1 levels, consid-
ered a biomarker of TAMs [43]. Similarly, this citokine
induces cathepsin protease activity in TAMs, where they
activate proteins including growth factors, transcription
factors, and other proteases, such as MMPs [44]. Ca-
thepsin B is considered a reliable marker for OSCC poor
prognosis, correlating to higher tumour grade and lymph
node metastasis [45].
IL-6
IL-6 expression in OSCC has been related to high lymph
node metastatic rates and poor tumour differentiation,
especially in male patients [46]. SDF-1alpha increases se-
cretion of IL-6 in cultured human OSCC cells via
CXCR4, ERK, and NF-κB pathways [47], in a similar
manner to that seen for IL-1β/IL-1R. Moreover, the ab-
errant synthesis of IL-6 by neoplastic cells may be con-
trolled by the CXCR4-specific inhibitor AMD3100 [47].
The calcium binding protein S100A9, associated with
loss of differentiation and recurrence, tends to be
deregulated in both tumour and stromal cells. The ex-
pression of S100A9 in monocytes exerts a tumour-
promoting effect upon co-culture with oral cancer cells,
in particular by releasing IL-6 and the activation of NF-
κB or STAT-3 that is not achieved in tumour cell
monoculture [48]. In response to apoptotic tumour cell
supernatants, signalling patterns were identified that
contributed to the TAMs phenotype. Two targets, IL-
4Rα and cannabinoid receptor 2 (CB2), were validated
and confirmed to regulate both IL-6 and IL-10 produc-
tion in TAMs, contributing to autocrine/paracrine acti-



















Fig. 1 Macrophages in resting state suffer microenvironmental effects coordinated by OSCC cells. Interleukin (IL)-1, IL-4, IL-6, IL-8 and IL-10 (not
shown), and Gas-6 are produced by OSCC cells and promote macrophage phenotype switching to an M2 polarization state. In turn, TAMs
augment the recruitment of chemotactic receptors to tumour sites, induce tumour proliferation, and favour angiogenesis and invasiveness
[31, 32, 36, 40–43, 47, 48, 65, 66]
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These findings emphasise the relevance of tumour cells
and TAMs interactions for disease progression.
IL-8
IL-8 is a pro-angiogenic, pro-inflammatory mediator im-
portant for OSCC angiogenesis progression [50]. The
mitogen activated protein kinases (MAPK) pathway is
used by OSCC IL-8 to activate angiogenic activity in
TAMs [51] augmenting, for example, vascular endothe-
lial growth factor (VEGF) production. The receptors
CXCR1 and CXCR2 have been detected in both oral
normal keratinocytes and OSCC cells, where they ex-
hibit higher expression. The presence of IL-8 CXC re-
ceptors in tumour cells increases ERK phosphorylation
and MMP-7 and MMP-9 release, representing a ten-
dency to proliferation, migration, and invasion [52]. Is
important to consider that matrix metalloproteinase en-
zymes are essential for the achievement of a complete
angiogenic potential of TAMs. At the same time, the
progressive development of the tumour requires vast
vasculature. Chronic periodontitis and tobacco con-
sumption have both historically been associated to oral
cancer. Then, recent published works propose the fol-
lowing interesting associations that also support the im-
portant role of IL-8 in OSCC progression. It is probable
that Porphyromonas gingivalis contributes to OSCC pro-
gression, increasing IL-8 levels in the microenvironment
and upregulating MMPs [53]. Nicotine also increases IL-
8 release in OSCC, binding to the nicotine acetylcholine
receptor (nAChR) and inducing calcium influx, that
phosphorylates Ca(2+)/calmodulin-dependent kinase II
(CaMK II) and NF-κB [54].
IL-10
In more dedifferentiated tumour niches the microenvir-
onment progressively acquires an immunosuppressive
profile [1–4]. IL-10 is a cytokine that modulates immune
responses, causing suppressive regulatory T cell differen-
tiation that contributes to tumour cell proliferation [55].
Since persistent viral infection promotes IL-10 upregula-
tion and impaired T-cell responses [56], it is believed
that this cytokine plays a critical role in human papil-
loma virus (HPV)- and Epstein-Barr virus (EBV)-related
OSCC progression [57, 58]. Moreover, IL-10 indicates
poor outcomes in HPV-unrelated OSCC, especially
when INF-γ secretion [59] and transforming growth fac-
tor beta 1 (TGF-β1) levels [60] are low. Receptors for
IL-22, a member of the IL-10 family, are highly
expressed in OSCC cells, including in metastatic sites,
compared to healthy regions. It was observed that in the
OSCC MISK81-5 cell line, IL-22 induced the transloca-
tion of phosphorylated STAT-3 and upregulated the ex-
pression of Bcl-xL, survivin, and c-Myc, all known anti-
apoptotic genes, as well as suppressor of cytokine
signalling 3 (SOCS3) [61]. In this context, diverse path-
ways for IL-10 production by TAMs have been
described, highlighting their contribution to an immuno-
suppressive state in the tumour stroma. TAMs present a
defective TLR response caused by tumour-selective dis-
ruption of the MyD88 signalling cascade, and affect the
TIR-domain-containing adapter-inducing interferon-β
(TRIF)/TNF receptor associated factors (TRAF3)-
dependent pathway in their own favour, leading to
favourable transcription at the IL-10 promoter region
[62]. In the presence of apoptotic tumour cell-factors
like sphingosine-1-phosphate (S1P), TAMs use tyrosine
kinase receptor A (TRKA), phosphatidylinositol 3-kinase
(PI3K)/protein kinase B (Akt), and MAPK signalling to
induce IL-10 [63].
Gas6/Axl
TAMs acquire, possibly by cancer-derived factors like
IL-10, the capacity to produce high levels of Gas-6 that
promotes tumour development [64]. At the same time,
in a bidirectional interaction, OSCC cells, that also pro-
duce Gas-6, polarize TAM toward a tumour-promoter
phenotype. In OSCC, Gas-6 cooperates with Axl and
achieves biological and clinical relevance by triggering
the signalling pathways of PI3/Akt and NF-κB [65].
TAMs and OSCC interact in Gas-6/Axl axis-modulated
epithelial-mesenchymal transition by upregulating cad-
herin, n-cadherin, and vimentin expression, and promot-
ing cell invasion and migration. It was found that Axl
expression correlates with clinical stage and lymph node
status in OSCC patients. Moreover, TAMs count was as-
sociated with phosphorylated Axl immunoactivity in
OSCC tissues [13, 65, 66]. Gas-6/Axl and NF-κB may be
interesting targets for therapeutic intervention, since
NF-κB promotes cancer resistance to apoptosis and pro-
duction of growth factors in the stroma, which stimu-
lates tumour progression [31].
Role of TAMs in OSCC histopathological diagnosis
Although further clinicopathological studies are needed
before interactions between stromal cells and malignant
cells can be defined as a key process for OSCC progres-
sion, evidence suggests that TAMs play several tumour-
promoter roles during carcinogenesis [10, 28]. The pres-
ence of these polarized cells should be used as a poten-
tial marker to distinguish incipient OSCC from invasive
lesions, avoiding underdiagnoses. As indicated by Mat-
waly et al. [67], the oral mucosa lacks an objective,
standard-like structure that is found in other anatomical
regions like the oesophagus, which makes the detection
of invasiveness in oral cancer demanding. For a better
understanding of TAMs in OSCC, more studies are ne-
cessary to define, by means of gene profiling, macro-
phage subpopulations with different tumour promoting
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abilities. A better indicator of the dynamic regulation of
macrophage phenotype may be cellular cytokines, evalu-
ated by means of tests conducted over multiple time
points [67]. However, this methodology is time and cost
demanding and probably unfeasible in clinical situations,
especially in less developed countries where the preva-
lence of OSCC is higher. However, from the available
evidence, it is possible to suggest that screening for
TAM markers in oral biopsies certainly may contribute
to accurate assessment of OSCC behaviour, being a valu-
able tool for the estimation of prognosis in cases related
and unrelated to viral infection [57–60, 68].
New diagnostic alternatives
Weber et al. [27] propose that even trauma from inci-
sional biopsies might influence tumour biology leading
to a worse prognosis and increased risk of developing
lymph node metastases in OSCC patients. A wound-
healing reaction consecutive to tissue trauma probably
provides a microenvironmental stimulus that affects
macrophage polarisation [69]. Until the present, diag-
nostic procedures and therapeutic planning for OSCC
have been supported mainly by histopathological find-
ings. Despite being inviable at present, mostly due to the
lack of standardized techniques, interpretation, and val-
idation of parameters, the development of new minimal
invasive diagnostic strategies should consider the screen-
ing of salivary and serum markers that reflect tumour
behaviour, associated or not with the improvement of
classical techniques like exfoliative cytology. Several
studies have demonstrated valuable associations among
OSCC clinical stages and prognosis, and salivary or
serum markers associated with TAM’s dynamic partici-
pation in the tumour stroma [58, 68, 70–73]. Although
salivary markers associated to TAM polarization are not
yet used as parameters for definitive diagnoses, they
should be taken into consideration to evaluate patients
with potent malignant disorders, like proliferative verru-
cous leukoplakia [74], as well as for recurrence in OSCC
treated patients.
Targeting TAMs in OSCC therapeutics
TAMs are potential targets for combination therapy in
cancer treatment [75]. As we move forward, comprehen-
sion of the role of stromal cells in OSCC progression,
suggest that therapies that only target TAMs may be
possible, leading to an imbalance in tumour growth and
invasiveness [75, 76]. However, despite its conceivable
relevance, essentially mostly from positive clinical impli-
cations, the research in this field is incipient among can-
cer researchers. Recently a few studies have proposed
targeting TAMs pathways to block cancer development
[77, 78]. Signalling pathways such as the NF-κB and cy-
tokines released in the tumour microenvironment
through OSCC cells and TAMs interactions are attract-
ive targets [79]. Inhibitors of cytokines involved in
tumour signalling present potential for use to combat
cancer, specially those implicated in promoting a malig-
nancy cycle between OSCC cells and TAMs. Consider-
ing that chirurgical approaches are gold standard
procedures for OSCC treatment, chemical interventions
would be considered of lesser importance. However, it is
relevant to underscore that during the last 30 years the
disease-free survival and overall survival rates of OSCC
patients have remained unchanged, perhaps due to lim-
ited care access or professional failures in performing
early diagnoses, which is of the utmost relevance for
prognosis. For these cases in particular, new therapeutic
options are urgently needed.
Conclusions
Impaired tumour-preventive responses in OSCC are
promoted by malignant cells and by soluble factors of
the microenvironment that attract and polarize macro-
phages to a tumour-promoting state. Besides, macro-
phages reinforce the loop that promotes cancer growth
and metastasis. This link between inflammation and can-
cer regulate OSCC progression and signalling pathways
that provide a cross-talk between cancer cells and TAMs
should be taken into consideration as valuable antineo-
plastic targets.
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